A Phase 4 clinical trial involving lixisenatide, as part of the combination iGlarLixi, was recorded as completed on July 10, 2026. The study, registered as NCT06716424 and titled "A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus," enrolled adult patients with type 2 diabetes mellitus.
The trial's status has moved to COMPLETED according to the registry entry. No results have been posted alongside this status update, and this brief does not characterize any outcomes, safety findings, or efficacy conclusions from the study.
The trial was conducted as a Phase 4 study, meaning it took place after the relevant products had already received regulatory approval. Phase 4 studies typically continue to monitor safety and efficacy in real world clinical use following approval.
Further details about the study design, patient population, and any eventual results may become available through the official clinical trial registry listing. Readers interested in the full trial record can consult the registry entry directly for updates.
For more background on lixisenatide, including its approved regulatory status and general information, readers can consult the compound overview.